EUnetHTA Joint Action 3 (2016-20)
2018 - PDF

Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint®

This is the assessment of the relative effectiveness of MammaPrint® - Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer

Below is the documentation provided by the Collaborative Assessment authoring team: